
Subtype and Stage Inference Model Implementation on LEADS tau PET

Marlene 2024 March

SuStaln Overview



Modeling subtype and stage simultaneously with event-based modeling:

- Events = the progression of biomarker(regional tau accumulation) to certain severity levels
- Subtypes = distinct sequences of events
- Stages = occurrences of events down the sequence

Assumptions:

1) arbitrary timescale


2) reconstruction of longitudinal trajectories

from cross-sectional data

3) Stable subtypes overtime – no crossover

4) monotonicity in biomarker level

Model Intuition



Model Intuition

Given

biomarker values (regional tau levels of patients) severity levels for each ROI


Determined through clustering


the most likely sequence of events (order of reaching severity levels)? the most likely proportions of different patterns in the data?

Data Preparation









 $X = \{x_{ij} \mid i = 1 \dots I, j = 1 \dots J\}$

 x_{ii} : mean SUVR of subject j in ROI i

Left & Right: Frontal Occipital Parietal Temporal MTL Lobar ROI

Study participants

Tabular data

tau PET images

SUVR images

L MTL L_frontal L_occipital L_parietal L_temporal R_MTL **R_frontal R_occipital R_parietal R_temporal** dx 1.212698 CN 1.029354 1.103603 1.074372 1.127232 1.210549 1.025647 1.109314 1.074605 1.142007 EOAD 1.856240 2.413739 2.957153 3.012157 2.856721 1.695600 2.197533 2.754564 2.772873 2.635381 1.744891 EOAD 1.329493 2.092321 2.439468 2.290511 1.271227 1.697044 1.870114 2.304942 2.221782


...

- LEADS (aβ- CN: 89; EOAD: 379) tau-PET images

- Co-registered to MRI, Normalized w.r.t. inferior cerebellar gray to derive SUVR images
- Parcellations using the Desikan-Killiany atlas (68 regions)
- Combined into ten lobar ROIs according to Vogel's
- For each ROI, calculate the volume-weighted mean SUVR

Standardization using GMM

Standardizaiton using the mean and SD of the 1st GMM component




- Two-component GMM (one for normal, one for abnormal) is fitted on all subjects for individual ROIs
- Then standardized using the mean and standard deviation of the normal component


$$\begin{aligned} X &= \{ x_{ij} \mid i = 1 \dots I, j = 1 \dots J \} \\ x_{ij} &= (x_{ij} - \mu_{\text{normal}}) / \sigma_{\text{normal}} \end{aligned}$$
 Data matrix
Standardization using μ_{normal} and σ_{normal}

Alt. Standardization

1-3 component GMM fit on mean SUVR in L_MTL (Best: K = 2)




Data-driven k-GMM confirmed most ROIs follow 2-GMM (exceptions: R & L occipitals)
 K = 1~6, optimized for 5-fold CV AIC



 Standardization using the mean and standard deviation of the CN group yields similar results (Pearson correlation coefficient ~ 1 for all ROIs)

Severity Levels



For ROI i, Z_{i1} , Z_{i2} , ... Z_{iR_i} (For each ROI) Severity levels are decided based on Z-scores

 $N = \sum_{i=1}^{I} R_i$

The total number of z-scores events in the sequence

- The event sequence S is then represented as a series of these events E_{iz} and has length N
- At the end of the event sequence (stage N), regional tau accumulates to their respective max levels
- In this implementation, all ROI has severity levels (arbitrarily chosen) of z = 2, 5, 10. N = 30.
- Alt.: the intersection of the 1st and 2nd component, mean±SD of the 2nd component

i.e., ROI1 = L_MTL, ROI2 = R_MTL, Z_{11} =1.43, Z_{12} =2.65, Z_{13} =6.96; Z_{21} =1.32, Z_{22} =2.17, Z_{13} =3.69; R_1 = R_2 =3.

Math

Prior Probability of individual belonging to a certain stage at time t (uniform)

$$P\left(\mathbf{X}|\mathbf{S}
ight) = \prod_{j=1}^{J} \left[\sum_{k=0}^{N} \left(\int_{t=rac{k}{N+1}}^{t=rac{k+1}{N+1}} \left(P(t) \prod_{i=1}^{I} P\left(x_{ij}|t
ight)
ight) \partial t
ight)
ight]$$

Young et al., Nat Commun 2018

Likelihood of tau levels at time t for subject j

Trajectory of tau accumulations between stage k and k+1 for subject j

Overall trajectories from stage 0 to N for subject j

Likelihoods for tau distribution data for all subjects (X) given the order of events) (S)

where,

Linear piecewise function that models tau accumulation in ROI i overtime


 $P\left(x_{ij}|t
ight) = ext{NormPDF}\left(x_{ij}|g_{i}\left(t
ight), \sigma_{i}
ight)$,


Probability of tau level at ROI i at time t for individual j follows normal distribution


Hence, considering all subtypes (C = number of clusters) for the data,

 $P\left(\mathbf{X}|\mathbf{M}
ight) = \sum_{c=1}^{C} f_{c} P\left(\mathbf{X}|\mathbf{S}_{c}
ight)$

M = the mixture of *z*-scores models fc = proportion of subjects belonging to a subtype c







Output

	Stage 1	Stage 2	Sum
Subtype 1			0.3
Subtype 2	0.1	0.4	0.5
Subtype 3			0.2

- Probabilities of individual subtype and stage assignment
- sequences for each subtype (with uncertainty)
- fractions of subjects belonging to each subtype

Hyperparameters:

- number of start points (25) = random initializations of
- sequence estimation/subtype assignments
- number of MCMC iterations (10⁵) = # of different


sequence orders examined to estimate uncertainty

- Number of Clusters (C = 7)


Cross-validation

Number of subtypes (C = 1^{7}) are decided using 10-fold cross-validation optimizing for the following criteria:

- Cross-validation information criteria
- Out-of-sample log likelihood
- Cross-validated maximum likelihood subtype probability




Derived subtype and stage (C=5)



- Positional variance diagram shows most likely event order in which the regional tau distribution reaches a certain severity (red, magenta, and blue for increasing levels) and the uncertainty in the ordering.
- Subtype 3 is the subtype with the least blurry positional variance graph, which translates to confidence in a predominant disease progression trajectory;
 In contrast to subtype 1 and 4, for example.

Model Assessment



- In each MCMC iteration a new set of parameter values (sequence orders) are evaluated and its resulting MLL is evaluated against the existing best.
- As the number of subtypes increases, the overall MLL also increase. And the MCMC traces show reasonable mixing property.

- Plotting distributions of the MLL derived from MCMC samples for each number of subtypes.
- The histograms again demonstrated as the number of subtypes increases, the MLL increases. The distributions are getting closer but no overlap is observed.

To-do

- Severity level choice
- CV criterion, graph/table replications (sans post-hoc)
- Compare results with Vogel's SuStaIn (Young's)
- Other ROI definitions, data transformation, clustering methods